Viesha A Ciura1, H Bart Brouwers1, Raffaella Pizzolato1, Claudia J Ortiz1, Jonathan Rosand1, Joshua N Goldstein1, Steven M Greenberg1, Stuart R Pomerantz1, R Gilberto Gonzalez1, Javier M Romero2. 1. From the Division of Neuroradiology, Department of Radiology (V.A.C., R.P., C.J.O., S.R.P., R.G.G., J.M.R.), Center for Human Genetic Research (H.B.B., J.R.), Division of Neurocritical Care and Emergency Neurology, Department of Neurology (H.B.B., J.R., J.N.G.), Department of Neurology, Hemorrhagic Stroke Research Group (H.B.B., J.R., J.N.G., S.M.G.), Department of Neurology, J. Philip Kistler Stroke Research Center (H.B.B., J.R., J.N.G.), and Department of Emergency Medicine (J.N.G.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands (H.B.B.). 2. From the Division of Neuroradiology, Department of Radiology (V.A.C., R.P., C.J.O., S.R.P., R.G.G., J.M.R.), Center for Human Genetic Research (H.B.B., J.R.), Division of Neurocritical Care and Emergency Neurology, Department of Neurology (H.B.B., J.R., J.N.G.), Department of Neurology, Hemorrhagic Stroke Research Group (H.B.B., J.R., J.N.G., S.M.G.), Department of Neurology, J. Philip Kistler Stroke Research Center (H.B.B., J.R., J.N.G.), and Department of Emergency Medicine (J.N.G.), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands (H.B.B.). jmromero@mgh.harvard.edu.
Abstract
BACKGROUND AND PURPOSE: The computed tomography angiography (CTA) spot sign is a validated biomarker for poor outcome and hematoma expansion in intracerebral hemorrhage. The spot sign has proven to be a dynamic entity, with multimodal imaging proving to be of additional value. We investigated whether the addition of a 90-second delayed CTA acquisition would capture additional intracerebral hemorrhage patients with the spot sign and increase the sensitivity of the spot sign. METHODS: We prospectively enrolled consecutive intracerebral hemorrhage patients undergoing first pass and 90-second delayed CTA for 18 months at a single academic center. Univariate and multivariate logistic regression were performed to assess clinical and neuroimaging covariates for relationship with hematoma expansion and mortality. RESULTS: Sensitivity of the spot sign for hematoma expansion on first pass CTA was 55%, which increased to 64% if the spot sign was present on either CTA acquisition. In multivariate analysis the spot sign presence was associated with significant hematoma expansion: odds ratio, 17.7 (95% confidence interval, 3.7-84.2; P=0.0004), 8.3 (95% confidence interval, 2.0-33.4; P=0.004), and 12.0 (95% confidence interval, 2.9-50.5; P=0.0008) if present on first pass, delayed, or either CTA acquisition, respectively. Spot sign presence on either acquisitions was also significant for mortality. CONCLUSIONS: We demonstrate improved sensitivity for predicting hematoma expansion and poor outcome by adding a 90-second delayed CTA, which may enhance selection of patients who may benefit from hemostatic therapy.
BACKGROUND AND PURPOSE: The computed tomography angiography (CTA) spot sign is a validated biomarker for poor outcome and hematoma expansion in intracerebral hemorrhage. The spot sign has proven to be a dynamic entity, with multimodal imaging proving to be of additional value. We investigated whether the addition of a 90-second delayed CTA acquisition would capture additional intracerebral hemorrhagepatients with the spot sign and increase the sensitivity of the spot sign. METHODS: We prospectively enrolled consecutive intracerebral hemorrhagepatients undergoing first pass and 90-second delayed CTA for 18 months at a single academic center. Univariate and multivariate logistic regression were performed to assess clinical and neuroimaging covariates for relationship with hematoma expansion and mortality. RESULTS: Sensitivity of the spot sign for hematoma expansion on first pass CTA was 55%, which increased to 64% if the spot sign was present on either CTA acquisition. In multivariate analysis the spot sign presence was associated with significant hematoma expansion: odds ratio, 17.7 (95% confidence interval, 3.7-84.2; P=0.0004), 8.3 (95% confidence interval, 2.0-33.4; P=0.004), and 12.0 (95% confidence interval, 2.9-50.5; P=0.0008) if present on first pass, delayed, or either CTA acquisition, respectively. Spot sign presence on either acquisitions was also significant for mortality. CONCLUSIONS: We demonstrate improved sensitivity for predicting hematoma expansion and poor outcome by adding a 90-second delayed CTA, which may enhance selection of patients who may benefit from hemostatic therapy.
Authors: S M Davis; J Broderick; M Hennerici; N C Brun; M N Diringer; S A Mayer; K Begtrup; T Steiner Journal: Neurology Date: 2006-04-25 Impact factor: 9.910
Authors: Adnan I Qureshi; Yuko Y Palesch; Renee Martin; Jill Novitzke; Salvador Cruz-Flores; Asad Ehtisham; Mustapha A Ezzeddine; Joshua N Goldstein; Jawad F Kirmani; Haitham M Hussein; M Fareed K Suri; Nauman Tariq; Yuan Liu Journal: Neurocrit Care Date: 2011-12 Impact factor: 3.210
Authors: Charlotte Jj van Asch; Merel Ja Luitse; Gabriël Je Rinkel; Ingeborg van der Tweel; Ale Algra; Catharina Jm Klijn Journal: Lancet Neurol Date: 2010-01-05 Impact factor: 44.182
Authors: Josser E Delgado Almandoz; Albert J Yoo; Michael J Stone; Pamela W Schaefer; Joshua N Goldstein; Jonathan Rosand; Alexandra Oleinik; Michael H Lev; R Gilberto Gonzalez; Javier M Romero Journal: Stroke Date: 2009-07-02 Impact factor: 7.914
Authors: Andrea Morotti; Javier M Romero; Michael J Jessel; Andrew M Hernandez; Anastasia Vashkevich; Kristin Schwab; Joseph D Burns; Qaisar A Shah; Thomas A Bergman; M Fareed K Suri; Mustapha Ezzeddine; Jawad F Kirmani; Sachin Agarwal; Angela Hays Shapshak; Steven R Messe; Chitra Venkatasubramanian; Katherine Palmieri; Christopher Lewandowski; Tiffany R Chang; Ira Chang; David Z Rose; Wade Smith; Chung Y Hsu; Chun-Lin Liu; Li-Ming Lien; Chen-Yu Hsiao; Toru Iwama; Mohammad Rauf Afzal; Christy Cassarly; Steven M Greenberg; Renee' Hebert Martin; Adnan I Qureshi; Jonathan Rosand; John M Boone; Joshua N Goldstein Journal: Neuroradiology Date: 2017-07-20 Impact factor: 2.804
Authors: A Morotti; J M Romero; M J Jessel; H B Brouwers; R Gupta; K Schwab; A Vashkevich; A Ayres; C D Anderson; M E Gurol; A Viswanathan; S M Greenberg; J Rosand; J N Goldstein Journal: AJNR Am J Neuroradiol Date: 2016-05-19 Impact factor: 3.825
Authors: David Rodriguez-Luna; Pilar Coscojuela; Marta Rubiera; Michael D Hill; Dar Dowlatshahi; Richard I Aviv; Yolanda Silva; Imanuel Dzialowski; Cheemun Lum; Anna Czlonkowska; Jean-Martin Boulanger; Carlos S Kase; Gord Gubitz; Rohit Bhatia; Vasantha Padma; Jayanta Roy; Alejandro Tomasello; Andrew M Demchuk; Carlos A Molina Journal: Neurology Date: 2016-06-24 Impact factor: 9.910
Authors: Jia Xu Lim; Julian Xinguang Han; Angela An Qi See; Voon Hao Lew; Wan Ting Chock; Vin Fei Ban; Sohil Pothiawala; Winston Eng Hoe Lim; Louis Elliot McAdory; Michael Lucas James; Nicolas Kon Kam King Journal: Neurocrit Care Date: 2019-04 Impact factor: 3.210